| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | GLAUKOS CORP | 2,603,362 | 64,277,000 | 26.88% | ||
| 2 | COLLEGIUM PHARMACEUTICAL INC COM | 1,877,332 | 51,627,000 | 21.59% | ||
| 3 | ProNAi Therapeutics, Inc. | 2,186,195 | 32,880,000 | 13.75% | ||
| 4 | AMICUS THERAPEUTICS INC | 2,918,291 | 28,307,000 | 11.84% | ||
| 5 | TOBIRA THERAPEUTICS INC | 2,668,570 | 26,819,000 | 11.21% | ||
| 6 | CIDARA THERAPEUTICS INC | 1,312,258 | 22,518,000 | 9.42% | ||
| 7 | IGNYTA INC COM | 950,366 | 12,735,000 | 5.32% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001420506-16-000752, filed 2016.02.11).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
